GLP-1 weight loss transformations: what TikTok skips over

What's this video probably claiming?

Based on the hashtags, @amyinhalf is almost certainly sharing a personal before-and-after weight loss transformation tied to GLP-1 receptor agonist use, likely semaglutide or tirzepatide. The #pcosweightloss tag suggests she may be framing GLP-1 medication as particularly effective for women with polycystic ovary syndrome. The #glp hashtag and the sheer volume of views (4.7 million) indicate this is doing what these videos typically do: presenting dramatic visual results with minimal clinical context, implying that the drug alone drove the transformation, and positioning the experience as broadly replicable. There may also be commentary about dose, timeline, or side effects, but the emphasis, as always in this genre, is the body change. That framing is not wrong exactly, but it is incomplete in ways that matter medically.

What does the science actually show?

GLP-1 receptor agonists do produce meaningful weight loss in clinical trials. The STEP 1 trial (Wilding et al., 2021, NEJM) showed semaglutide 2.4 mg weekly produced an average 14.9% body weight reduction over 68 weeks in adults with obesity. The SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM) showed tirzepatide at 15 mg achieved up to 20.9% weight reduction over 72 weeks. Those are real numbers. For PCOS specifically, a 2023 systematic review in Reproductive BioMedicine Online found GLP-1 agonists improved insulin resistance, menstrual regularity, and body weight in women with PCOS, though most studies were small and short-term. What these trials also show, and what TikTok transformations rarely address, is that results vary substantially by individual, and that discontinuation leads to significant weight regain. The STEP 4 trial (Rubino et al., 2021, JAMA) found participants regained two-thirds of lost weight within a year of stopping semaglutide.

Where does the social media noise diverge from clinical reality?

The biggest gap between transformation content and clinical reality is survivorship bias. You are watching the person for whom the drug worked well enough to post about it. You are not watching the estimated 20-30% of patients who discontinue due to gastrointestinal side effects (Wilding et al., 2021), or the people who lost modest weight and felt the result did not justify the cost or discomfort. The PCOS angle introduces another layer of complexity. GLP-1s are not FDA-approved specifically for PCOS, meaning their use in that context is off-label. The insulin-sensitizing mechanism does address a core PCOS driver, but the evidence base is thinner than transformation videos imply. There is also the cost and access problem. Wegovy and Zepbound list above $900 per month without insurance, which these videos almost never mention. Personal transformation content, even when honest, functions as implicit advertising for a class of drugs that requires clinical supervision, dose titration, and ongoing monitoring.

What should you actually know?

GLP-1 medications are legitimate, well-studied tools for weight management, not a shortcut or a hack. The results in transformation videos are real but represent the upper range of outcomes, not the average. If you have PCOS and are considering a GLP-1 agonist, that is a reasonable conversation to have with a prescribing clinician who can evaluate your metabolic panel, insulin levels, and cardiovascular risk factors. What it is not is a conversation to initiate based on a TikTok. Dose matters enormously. The weight loss seen in SURMOUNT-1 at tirzepatide 15 mg is not what happens at 2.5 mg, where the average loss was closer to 6%. Side effect profiles, contraindications including a personal or family history of medullary thyroid carcinoma, and drug interactions require individual assessment. Compounded semaglutide and tirzepatide are not equivalent to FDA-approved branded formulations, and the FDA has raised quality concerns about some compounded versions. Any platform or creator that glosses over these distinctions is giving you marketing, not medicine.